Oncotarget

Research Papers:

A hemoglobin-based oxygen carrier sensitized Cisplatin based chemotherapy in hepatocellular carcinoma

Xiang Qi, Bing L. Wong, Sze Hang Lau, Kevin Tak-Pan Ng, Sui Yi Kwok, Chris Kin-Wai Sun, Fei Chuen Tzang, Yan Shao, Chang Xian Li, Wei Geng, Chang Chun Ling, Yuen Yuen Ma, Xiao Bing Liu, Hui Liu, Jiang Liu, Wai Ho Yeung, Chung Mau Lo and Kwan Man _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:85311-85325. https://doi.org/10.18632/oncotarget.19672

Metrics: PDF 1787 views  |   HTML 1903 views  |   ?  


Abstract

Xiang Qi1, Bing L. Wong3, Sze Hang Lau3, Kevin Tak-Pan Ng1, Sui Yi Kwok3, Chris Kin-Wai Sun3, Fei Chuen Tzang3, Yan Shao1, Chang Xian Li1, Wei Geng1, Chang Chun Ling1, Yuen Yuen Ma1, Xiao Bing Liu1, Hui Liu1, Jiang Liu1, Wai Ho Yeung1, Chung Mau Lo1,2 and Kwan Man1,2

1Department of Surgery, The University of Hong Kong, Hong Kong, China

2Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China

3New β Innovation Limited, 18/F Chevalier Commercial Centre, Hong Kong, China

Correspondence to:

Kwan Man, email: kwanman@hku.hk

Keywords: hemoglobin-based oxygen carrier, chemoresistance, HCC, Cisplatin, intravital imaging

Received: April 04, 2017    Accepted: May 11, 2017    Published: July 28, 2017

ABSTRACT

Background and Objective: Our previous study showed that liver graft injury not only promotes tumor recurrence, but also induces chemoresistance in recurrent HCC after liver transplantation. Recently, we found that the hemoglobin-based oxygen carrier“YQ23” significantly ameliorates hepatic IR injury and prevent tumor recurrence. Here, we intended to explore the novel therapeutic strategy using oxygen carrier “YQ23”to sensitize chemotherapy in HCC.

Methods: To investigate the role of YQ23 combined with Cisplatin, the proliferation of HCC cells was examined under combined treatment by MTT and colony formation. To explore the effect of YQ23 on sensitization of Cisplatin based chemotherapy, the orthotopic liver cancer model was established. To characterize the delivery of YQ23 in tumor tissue, the intravital imaging system was applied for longitudinal observation in ectopic liver cancer model. The distribution of YQ23 was examined by IVIS spectrum.

Results: YQ23 significantly suppressed the proliferation of HCC cells under Cisplatin treatment in a dose and time dependent manner. Moreover, YQ23 administration significantly sensitized Cisplatin based chemotherapy in orthotopic liver cancer model. Down-regulation of DHFR may be one of the reasons for YQ23 sensitizing Cisplatin based chemotherapy. Real-time intravital imaging showed that YQ23 accumulated in the tumor tissue and maintained as long as 3 days in ectopic liver cancer model. The IVIS spectrum examination showed that YQ23 distributed mainly at liver and bladder within the first 36 hours after administration in orthotopic liver cancer model.

Conclusion: YQ23 treatment may be a potential therapeutic strategy to sensitize chemotherapy in HCC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 19672